Market Intelligence, Clinical Progress, and High-Purity Reagents for Deafness, Fibrosis, and Oncology Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MYH14 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MYH14 Motor Domain Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW 120–220 kDa. | View MYH14 Products |
| Gene Delivery | MYH14 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. HEK293 expressed. | View MYH14 Products |
| Benchmark Ab | Anti-MYH14 (Pan-Myosin II-C Specific). Recombinant monoclonal for WB/IHC/IP control. | View MYH14 Products |
| Validator | MYH14 siRNA Set. For knockdown verification and specificity control. | View MYH14 Products |
| Related Target: MYH9 | Non-muscle Myosin Heavy Chain II-A. Isoform selectivity counter-screening (high homology). | View MYH9 Products |
| Related Target: MYH10 | Non-muscle Myosin Heavy Chain II-B. Compensatory isoform analysis. | View MYH10 Products |
| Related Target: ROCK1 | Upstream kinase regulating myosin light/heavy chain cytoskeleton dynamics. | View ROCK1 Products |
| Related Target: ACTB | Beta-Actin (Binding Partner). For actin-myosin co-sedimentation assays. | View ACTB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (MYH9/10/14) | Human/Mouse/Cyno ortholog proteins available with >95% purity; strict sequence verification by mass spec to distinguish II-A, II-B, II-C isoforms. |
| ATPase Activity Screening | Motor domain constructs with verified ATP-binding capacity; suitable for malachite green or TR-FRET endpoints; native folding for functional screening. |
| Cell Permeability Validation | High-expression lentivirus systems for stable reporter cell lines; endotoxin controlled <1EU/ug. |
| Lack of Specific Controls | Sequence-verified antibodies specific to unique MYH14 C-terminus; pan-myosin and isoform-specific antibodies included for Western validation. |
| False Positives in Cell Assays | Validated siRNA included for specificity checks. |
Live MYH14 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for MYH14 (non-muscle myosin heavy chain II-C) remains emergent, with current focus concentrated on three major axes: genetic hearing loss (DFNA4), tissue fibrosis (e.g., IPF), and cancer metastasis. As first-generation pan-myosin inhibitors face specificity challenges in the clinic, the next wave of R&D is targeting isoform-selective allosteric sites, siRNA approaches for autosomal dominant mutations, and small molecule ATPase inhibitors to modulate cytoskeletal dynamics during tumor invasion. Major players include Calico Life Sciences (fibrosis), Novartis (oncology), and academic centers advancing gene therapy for DFNA4. The race is intensifying to overcome high sequence homology with paralogs MYH9 and MYH10, necessitating rigorous isoform-specific assay systems.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA / Gene Therapy | Academic / Early Biotech; Otonomy | DFNA4 (Hearing Loss) | Cell line validation: high-titer lentivirus for expression and silencing. |
| Small Molecule (Allosteric) | Calico Life Sciences, Bioage Labs | Idiopathic Pulmonary Fibrosis (IPF) | ATPase activity assay: high-purity motor domain with native folding. |
| Small Molecule (ATP-competitive) | Novartis, Biogen | Metastatic Solid Tumors | Selectivity panel: MYH9/MYH10/MYH14 homolog proteins strictly verified by mass spec. |
| PROTAC / Degrader | Arvinas (exploratory), Academic consortia | Oncology | Cell-based degradation assay: high-expression lentivirus cell lines for target engagement. |
| Biomarker Diagnostic | Oncology Diagnostics | Cancer Prognostics | IHC validation: highly specific antibodies for tissue analysis. |
Key Mutations and Functional Domains
MYH14 encodes the non-muscle myosin heavy chain II-C (NMHC II-C). Key functional domains include: Myosin N-terminal SH3-like domain, Myosin motor domain (ATPase and actin-binding), and IQ motifs. Clinically relevant mutations are linked to autosomal dominant deafness (DFNA4A), notably rs119103281, as well as variants rs200424400 and rs34498817. These mutations underscore the need for isoform-selective tools and mutation-specific assay systems in drug development.